Journal of Molecular Medicine, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 6, 2024
Language: Английский
Nature Reviews Genetics, Journal Year: 2024, Volume and Issue: 25(8), P. 578 - 595
Published: Feb. 29, 2024
Language: Английский
Citations
65
Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)
Published: June 20, 2024
Abstract RNA methylation, a prevalent post-transcriptional modification, has garnered considerable attention in research circles. It exerts regulatory control over diverse biological functions by modulating splicing, translation, transport, and stability. Notably, studies have illuminated the substantial impact of methylation on tumor immunity. The primary types encompass N6-methyladenosine (m6A), 5-methylcytosine (m5C), N1-methyladenosine (m1A), N7-methylguanosine (m7G), 3-methylcytidine (m3C). Compelling evidence underscores involvement regulating microenvironment (TME). By affecting translation stability through "writers", "erasers" "readers", influence dysregulation immune cells factors. Consequently, plays pivotal role immunity mediating various behaviors, encompassing proliferation, invasion, metastasis, etc. In this review, we discussed mechanisms several methylations, providing comprehensive overview their roles underlying within among immunocytes. exploring how these modifications mediate evasion, also examine potential applications immunotherapy. This review aims to provide novel insights strategies for identifying targets advancing cancer immunotherapy efficacy.
Language: Английский
Citations
30
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: Nov. 29, 2024
Language: Английский
Citations
13
Cancers, Journal Year: 2024, Volume and Issue: 16(1), P. 234 - 234
Published: Jan. 4, 2024
Metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) is a long intergenic non-coding RNA (lncRNA) located on chr11q13. It overexpressed in several cancers and controls gene expression through chromatin modification, transcriptional regulation, post-transcriptional regulation. Importantly, MALAT-1 stimulates cell proliferation, migration, metastasis serves vital role driving the epithelial-to-mesenchymal transition (EMT), subsequently acquiring cancer stem cell-like properties developing drug resistance. modulates EMT by interacting with various intracellular signaling pathways, notably phosphoinositide 3-kinase (PI3K)/Akt Wnt/β-catenin pathways. also behaves like sponge for microRNAs, preventing their interaction target genes promoting EMT. In addition, we have used bioinformatics online tools to highlight disparities of between normal samples using data from The Cancer Genome Atlas (TCGA). Furthermore, intricate interplay essential targets progression renders it good candidate therapeutic interventions. Several innovative approaches been exploited MALAT-1, such as short hairpin RNAs (shRNAs), antisense oligonucleotides (ASOs), natural products. This review emphasizes modulating metastasis, stemness, chemoresistance different cancers.
Language: Английский
Citations
12
Advanced Science, Journal Year: 2024, Volume and Issue: 11(24)
Published: April 19, 2024
Abstract M2‐polarized tumor‐associated macrophages (M2 TAMs) promote cancer progression. Exosomes mediate cellular communication in the tumor microenvironment (TME). However, roles of exosomes from M2 TAMs gastric progression are unclear. Herein, it is reported that TAMs‐derived induced aerobic glycolysis cells and enhanced their proliferation, metastasis, chemoresistance a glycolysis‐dependent manner. It identified MALAT1 (metastasis‐associated lung adenocarcinoma transcript 1) enriched TAM confirmed transfer to via mediates this effect. Mechanistically, interacted with δ‐catenin protein suppressed its ubiquitination degradation by β‐TRCP. In addition, upregulated HIF‐1α expression acting as sponge for miR‐217‐5p. The activation β‐catenin signaling pathways collectively led cells. Finally, dual‐targeted inhibition both exosome‐mediated delivery siRNA remarkably growth improved chemosensitivity mouse models. Taken together, these results suggest ‐mediated regulation glycolysis. findings offer potential target therapy.
Language: Английский
Citations
12
Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 2940 - 2940
Published: Aug. 23, 2024
Advancements in our comprehension of tumor biology and chemoresistance have spurred the development treatments that precisely target specific molecules within body. Despite expanding landscape therapeutic options, there persists a demand for innovative approaches to address unmet clinical needs. RNA therapeutics emerged as promising frontier this realm, offering novel avenues intervention such interference utilization antisense oligonucleotides (ASOs). ASOs represent versatile class capable selectively targeting messenger RNAs (mRNAs) silencing disease-associated proteins, thereby disrupting pathogenic processes at molecular level. Recent advancements chemical modification carrier molecule design significantly enhanced stability, biodistribution, intracellular uptake ASOs, bolstering their potential. While ASO therapy holds promise across various disease domains, including oncology, coronary angioplasty, neurological disorders, viral, parasitic diseases, review manuscript focuses specifically on application targeted cancer therapies. Through comprehensive examination latest research findings developments, we delve into intricacies ASO-based treatment, shedding light mechanisms action, efficacy, prospects.
Language: Английский
Citations
7
Frontiers in Genetics, Journal Year: 2024, Volume and Issue: 15
Published: March 1, 2024
Introduction: Long non-coding RNAs (lncRNAs) have been in the clinical use as potential prognostic biomarkers of various types cancer. Identifying associations between lncRNAs and diseases helps capture design efficient therapeutic options for diseases. Wet experiments identifying these are costly laborious. Methods: We developed LDA-SABC, a novel boosting-based framework lncRNA–disease association (LDA) prediction. LDA-SABC extracts LDA features based on singular value decomposition (SVD) classifies pairs (LDPs) by incorporating LightGBM AdaBoost into convolutional neural network. Results: The performance was evaluated under five-fold cross validations (CVs) lncRNAs, diseases, LDPs. It obviously outperformed four other classical inference methods (SDLDA, LDNFSGB, LDASR, IPCAF) through precision, recall, accuracy, F1 score, AUC, AUPR. Based accurate prediction we used it to find lncRNA lung results elucidated that 7SK HULC could relationship with non-small-cell cancer (NSCLC) adenocarcinoma (LUAD), respectively. Conclusion: hope our proposed method can help improve identification.
Language: Английский
Citations
6
Cancers, Journal Year: 2024, Volume and Issue: 16(2), P. 290 - 290
Published: Jan. 10, 2024
Breast cancer stem cells (BCSCs) is a subpopulation of with self-renewal and differentiation capacity, have been suggested to give rise tumor heterogeneity biologically aggressive behavior. Accumulating evidence has shown that BCSCs play fundamental role in tumorigenesis, progression, recurrence. The development immunotherapy, primarily represented by programmed cell death protein 1 (PD-1)/programmed death-ligand (PD-L1) inhibitors, greatly changed the treatment landscape multiple malignancies. Recent studies identified pervasive negative associations between stemness anticancer immunity. Stemness seems causative formation cold immune microenvironment (TIME). functions long non-coding RNAs (lncRNAs) regulating responses recently highlighted breast cancer. review focus on lncRNAs keys pathways involved regulation TIME. Potential clinical applications using as biomarkers or therapies will be discussed.
Language: Английский
Citations
4
Cancer Letters, Journal Year: 2024, Volume and Issue: 592, P. 216906 - 216906
Published: April 21, 2024
Language: Английский
Citations
4
Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15
Published: April 1, 2025
Gastric cancer (GC) is an exceedingly aggressive disease and ranks as the third leading cause of cancer-related deaths, which poses a huge health burden globally. Chemotherapy commonly employed during middle to advanced stages cancer, although it faces frequent treatment failures attributed drug resistance. Thus, imperative for researchers identify potential targets overcoming therapeutic resistance, thereby facilitating development novel anti-cancer agents GC patients with stages. Long noncoding RNAs (lncRNAs) are diverse group transcripts limited protein-coding capacity, have been recognized functional molecules regulating progression including cell proliferation, metastasis, resistance in GC. In this review, we examine intricate molecular networks on role lncRNAs LncRNAs conferred through various mechanisms, therefore functioning promising patients. Additionally, discuss current advancements strategies targeting therapy, may pave way lncRNA-mediated precision medicine malignant disease.
Language: Английский
Citations
0